参考文献/References:
[1] Fan JG,Farrell GC．Epidemiology of non-alcoholic fatty liver disease in China[J]．J Hepatol,2009,50（1）：204-210.
[2] Cable EE,Finn PD,Stebbins JW,et al．Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist[J]．Hepatology,2009,49（2）：407-417.
[3] Adams AC,Astapova I,Fisher FM,et al．Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner[J]．J Biol Chem,2010,285（19）：14078-14082.
[4] Musso G,Gambino R,Cassader M．Emerging molecular targets for the treatment of nonalcoholic fatty liver disease[J]．Annu Rev Med,2010,61：375-392.
[5] Almeda-Valdés P,Cuevas-Ramos D,Aguilar-Salinas CA． Metabolic syndrome and non-alcoholic fatty liver disease[J]．Ann Hepatol,2009,8 （Suppl 1）：S18-S24.
[6] Chen SH,He F,Zhou HL,et al．Relationship between nonalco-holic fatty liver disease and metabolic syndrome[J]．J Dig Dis,2011,12（2）：125-130.
[7] Erdogan M,Canataroglu A,Ganidagli S,et al．Metabolic syndrome prevalence in subclinic and overt hypothyroid patients and the relation among metabolic syndrome parameters[J]．J Endocrinol Invest,2011,34（7）：488-492.
[8] Mazo DF,Lima VM,Stefano JT,et al．Gluco-lipidic indices in treated hypothyroidism associated with nonalcoholic fatty liver disease[J]．Arq Gastroenterol,2011,48（3）：186-189.
[9] Gnoni GV,Rochira A,Leone A,et al．3,5,3'triiodo-L-thyronine induces SREBP-1 expression by non-genomic actions in human HEP G2 cells[J]．J Cell Physiol,2012,227（6）：2388-2397.
[10] Perra A,Simbula G,Simbula M,et al．Thyroid hormone （T3） and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats[J]．FASEB J,2008,22（8）：2981-2989.
[11] Lewis JR,Mohanty SR．Nonalcoholic fatty liver disease：a review and update[J]．Dig Dis Sci,2010,55（3）：560-578.
[12] Messarah M,Boumendjel A,Chouabia A,et al．Influence of thyroid dysfunction on liver lipid peroxidation and antioxidant status in experimental rats[J]．Exp Toxicol Pathol,2010,62（3）：301-310.
[13] Silveira MG,Mendes FD,Diehl NN,et al．Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease[J]．Liver Int,2009,29（7）：1094-1100.
[14] Cahová M,Daňková H,Pálenícková E,et al．The autophagy-lysosomal pathway is involved in TAG degradation in the liver：the effect of high-sucrose and high-fat diet[J]．Folia Biol （Praha）,2010,56（4）：173-182.
[15] Yang L,Li P,Fu S,et al．Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance[J]．Cell Metab,2010,11（6）：467-478.
[16] Rautou PE,Mansouri A,Lebrec D,et al．Autophagy in liver diseases[J]．J Hepatol,2010,53（6）：1123-1134.
[17] Tacke F,Trautwein C．Controlling autophagy：a new concept for clearing liver disease[J]．Hepatology,2011,53（1）：356-358.
[18] Sinha RA,You SH,Zhou J,et al．Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy[J]．J Clin Invest,2012,122（7）：2428-2438.
[19] Arrese M．Burning hepatic fat：therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease[J]．Hepatology,2009,49（2）：348-351.
[20] Lim EL,Hollingsworth KG,Aribisala BS,et al．Reversal of type 2 diabetes：normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol[J]．Diabetologia,2011,54（10）：2506-2514.
[21] Fox CS,Pencina MJ,D'Agostino RB,et al．Relations of thyroid function to body weight：cross-sectional and longitudinal observations in a community-based sample[J]．Arch Intern Med,2008,168（6）：587-592.
[22] Jornayvaz FR,Lee HY,Jurczak MJ,et al．Thyroid hormone receptor-alpha gene knockout mice are protected from diet-induced hepatic insulin resistance[J]．Endocrinology,2012,153（2）：583-591.
[23] Pelletier P,Gauthier K,Sideleva O,et al．Mice lacking the thyroid hormone receptor-alpha gene spend more energy in thermogenesis, burn more fat,and are less sensitive to high-fat diet-induced obesity[J]． Endocrinology,2008,149（12）：6471-6486.
[24] Villicev CM,Freitas FR,Aoki MS,et al．Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats[J]．J Endocrinol,2007,193（1）：21-29.
[25] Grover GJ,Egan DM,Sleph PG,et al．Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates：selective actions relative to 3,5,3'-triiodo-L-thyronine[J]． Endocrinology,2004,145（4）：1656-1661.
相似文献/References:
[1]刘丹,徐书杭,陈国芳,等.甲状腺激素对胰岛β细胞功能的调控[J].国际内分泌代谢杂志,2014,(01):18.[doi:10.3760/cma.j.issn.1673-4157.2014.01.005]
Liu Dan*,Xu Shuhang,Chen Guofang,et al.Regulation of thyroid hormone on islet β cells[J].International Journal of Endocrinology and Metabolism,2014,(01):18.[doi:10.3760/cma.j.issn.1673-4157.2014.01.005]
[2]郑楠,袁继红,刘欣,等.甲状腺激素促进肿瘤细胞增殖及血管新生信号通路的研究[J].国际内分泌代谢杂志,2014,(03):149.[doi:10.3760/cma.j.issn.1673-4157.2014.03.002]
Zheng Nan,Yuan Jihong,Liu Xin,et al.Signaling pathway of thyroid hormone on the promotion of tumor cell proliferation and angiogenesis[J].International Journal of Endocrinology and Metabolism,2014,(01):149.[doi:10.3760/cma.j.issn.1673-4157.2014.03.002]
[3]党萍萍,滕卫平,单忠艳,等.遗传性甲状腺素结合球蛋白异常的研究进展[J].国际内分泌代谢杂志,2023,43(03):221.[doi:10.3760/cma.j.cn121383-20220310-03025]
Dang Pingping,Teng Weiping,Shan Zhongyan,et al.Progress in hereditary thyroxin-binding globulin abnormality research[J].International Journal of Endocrinology and Metabolism,2023,43(01):221.[doi:10.3760/cma.j.cn121383-20220310-03025]